Detalhe da pesquisa
1.
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
N Engl J Med
; 2024 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38828984
2.
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Lancet Oncol
; 22(6): 836-847, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33989557
3.
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.
Lancet Oncol
; 22(8): e343-e344, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34339647
4.
Acrocyanosis after neoadjuvant ipilimumab plus nivolumab: a case report.
Clin Exp Rheumatol
; 38(5): 1031-1032, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32301417
5.
Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma.
Cancer Discov
; 13(11): 2319-2338, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37668337
6.
Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence.
Cancer Res Commun
; 3(4): 672-683, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37089863
7.
Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells.
Cancer Immunol Res
; 11(4): 450-465, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36753604
8.
Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma.
Nat Med
; 29(12): 3090-3099, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37957378
9.
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.
J Exp Med
; 220(5)2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36920329
10.
Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma.
JAMA Surg
; 157(4): 335-342, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35138335
11.
Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.
Nat Med
; 28(11): 2344-2352, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36138151
12.
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.
Nat Med
; 28(6): 1178-1188, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35661157
13.
Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.
Eur J Cancer
; 148: 51-57, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33735809
14.
Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma.
Pigment Cell Melanoma Res
; 33(3): 498-506, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31646741